Form 4: 10x Genomics CEO Serge Saxonov Receives RSU Grant

10x Genomics CEO Serge Saxonov was granted 157,895 restricted stock units, aligning his interests with long-term shareholder value.

Summary

• Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (TXG), acquired 157,895 Class A Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on February 26, 2026, with a price of $0 per share, which is typical for RSU grants.
• These RSUs represent a contingent right to receive one share of Class A Common Stock upon vesting.
• Vesting will occur quarterly, with 1/12th of the RSUs vesting on each quarterly anniversary starting from February 21, 2026, contingent on Saxonov's continued service.
• Following this transaction, Saxonov directly owns 1,219,819 Class A Common Stock.
• He also indirectly owns shares through the Andromeda Trust (27 shares), Y/S Descendants' Trust (213,250 shares), and Y/S Pot Trust (58,000 shares), for which he serves as trustee.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as it signifies continued executive commitment and aligns the CEO's financial interests with the company's long-term performance, which is generally favorable for shareholders.

Positives

• The grant of 157,895 Restricted Stock Units (RSUs) to CEO Serge Saxonov aligns his compensation with the long-term performance of 10x Genomics, Inc.
• The vesting schedule, contingent on continued service, incentivizes leadership stability and sustained commitment to company growth.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports an executive compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedule for the granted Restricted Stock Units indicates a future commitment from Serge Saxonov to continue as a service provider to 10x Genomics, Inc., with vesting occurring quarterly from February 21, 2026.

Industry Context

StockSavvy.ai notes that RSU grants are a standard component of executive compensation packages in the biotechnology and life sciences industries, aiming to align executive interests with shareholder value over the long term. This particular grant to the CEO of 10x Genomics is consistent with typical practices for retaining and incentivizing key leadership in growth-oriented technology companies.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a CEO is a common practice across the technology and life sciences sectors, comparable to compensation structures at companies like Illumina (ILMN) or Pacific Biosciences (PACB), which frequently use equity awards to incentivize executive performance and retention.
• The vesting schedule, typically over several years and contingent on continued service, is standard for such grants, ensuring long-term alignment rather than short-term gains.

Stakeholder Impact

• Shareholders: The RSU grant aligns the CEO's financial incentives with the long-term performance of the company, potentially benefiting shareholders through sustained leadership and strategic focus.
• Employees: Continued leadership stability from the CEO, incentivized by long-term equity, can foster a more stable and focused work environment.

Next Steps

• Quarterly vesting of the 157,895 Restricted Stock Units, commencing from February 21, 2026, contingent on Serge Saxonov's continued service.

Key Dates

Keywords

10x Genomics, TXG, Serge Saxonov, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, SEC Filing, Equity Grant